Search company, investor...

Nectar Life Sciences

nectarlifesciences.com

Founded Year

2021

Stage

Series A | Alive

Total Raised

$24.5M

Last Raised

$16.5M | 2 mos ago

About Nectar Life Sciences

Nectar is building a comprehensive, vertically integrated allergy healthcare platform that leverages data and clinical research to offer a personalized, patient-centric approach to allergy care. It operates a telehealth platform that specializes in custom allergy treatments that connect patients to online physicians and pharmacists who prescribe custom at-home treatment plans that get to the root cause of the allergies. The company was founded in 2021 and is based in New York, New York.

Headquarters Location

30 Cooper Square Floor 10

New York, New York, 10003,

United States

Missing: Nectar Life Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Nectar Life Sciences

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

The companies in this market develop digital therapeutics to help control allergies. With the goal of lessening symptons, these startups look at food sensitivities and environmental triggers to understand the root causes and improve daily life.

Nectar Life Sciences named as Leader among 8 other companies, including Ro, Intrommune Therapeutics, and Bioherent.

Missing: Nectar Life Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nectar Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nectar Life Sciences is included in 2 Expert Collections, including Digital Health.

D

Digital Health

13,069 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

T

Telehealth

2,856 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Latest Nectar Life Sciences News

Nectar Raises over $24M in Funding to Scale Personalized Allergy Care Platform Nationally

Dec 21, 2022

Venture Capital News | Private Equity News venture capital directory | private equity directory Venture Capital Firms List / Venture Capital & Private Equity Firms and Sources Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory 2022 Newly Updated Edition Now Available! (Updated JULY 2022) VCPro Database 2022 25th Edition — a downloadable and searchable venture capital database with 6,800+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. Nectar Raises over $24M in Funding to Scale Personalized Allergy Care Platform Nationally Investment from venture funds Juxtapose, Obvious Ventures, and Harmony Partners will help Nectar launch its comprehensive allergy care program nationwide. NEW YORK, December 20, 2022-- Nectar, an innovative and comprehensive allergy care platform, announced today its $16.5 million Series A round led by Harmony Partners, with meaningful participation from founding partners Juxtapose and Obvious Ventures, who co-built the company with Founding CEO Kenneth Chahine, Ph.D. Nectar's latest fundraising round, which builds on their March 2022 seed investment and brings total equity raised to over $24M, will allow the company to invest in three key areas in 2023: scaling its virtual care platform nationwide, launching its first physical location to comprehensively treat allergies, and initiating clinical studies. Nectar is the consumer-facing brand of Nectar Life Sciences, an allergy-focused healthcare holding company led by Dr. Chahine, one of the country's leading entrepreneurial operators at the intersection of science and healthcare. Nectar launched in June 2022 with a mission to turn clinical research into personalized, accessible, and revolutionary allergy care and ultimately put an end to allergies. "Today, over 120 million people in the US suffer from allergic diseases, yet most consumers feel under-served and constrained with the therapies available to them," said Nectar's Dr. Chahine. "We're proud to tackle this chronic illness head-on with transformative personalized solutions that holistically treat the unique root cause of an individual's allergies while also focusing on convenience and an exceptional customer experience." Nectar is building the first vertically-integrated platform for allergies, including a hybrid virtual and physical clinic model, compounding pharmacy, lab testing facility, and an allergist physician network to align incentives and deliver best-in-class customer experiences. Nectar's world-class medical board advises on every aspect of Nectar's comprehensive allergy treatment program. It also helps drive clinical research efforts, ensuring all products and services meet the highest safety and efficacy standards. In November, three scientific and clinical experts joined Nectar's Head of Medical, Shyam Joshi, M.D. on the company's medical board, including Kari Nadeau, M.D., Ph.D., Stanford University, Mohamed Shamji, Ph.D., Imperial College London, and John Zwetchkenbaum, M.D., Chief Allergist and Founder of AAPRI. "Nectar's mix of cutting-edge scientific research, strong business and medical leaders, and an industry-changing approach to conquering allergies, made our choice to partner an easy one," said Mark Lotke, Founder and Managing Partner at Harmony Partners. "We're proud to help fuel Nectar's transformative work as it scales its virtual care platform nationwide." Nectar's inaugural solution, an alternative to allergy shots, offers custom-formulated drops for under the tongue, delivered right to patients' homes. The dosage and formulation of the treatment come from patent-pending protocols that help a patient's body tolerate their allergen triggers over time through a process called Sublingual Allergen Immunotherapy, training their immune system not to trigger an allergic reaction. "Allergy care is a $450 billion market opportunity with no clear leader. Dr. Chahine's impressive track record, including his role in founding AncestryDNA and Ancestry Health, makes him the perfect leader to build and grow Nectar," said Patrick Chun, Co-founder and Managing Partner of Juxtapose. "We're thrilled to be partnering with Harmony and Juxtapose to help accelerate the success of Nectar," said James Joaquin, Co-founder and Managing Director of Obvious Ventures. "Together we plan to improve the lives of millions of allergy sufferers." Learn more at mynectar.com. About Nectar Life Sciences Nectar is building a comprehensive, vertically integrated allergy healthcare platform that leverages data and clinical research to offer a personalized, patient-centric approach to allergy care. Led by founder and CEO Kenneth Chahine, Nectar is the direct-to-consumer brand developed by Nectar Life Sciences. About Harmony Partners Harmony Partners is a highly differentiated venture capital firm that makes expansion-stage investments in high-growth software, internet and tech-enabled companies. By eliminating the typical deal constraints of traditional growth equity firms around minimum check sizes and ownership percentages, Harmony fills a gap in the market. Harmony helps entrepreneurs craft ideal financings, minimize founder dilution, and save time and effort while accommodating outsized insider appetite and making room for strategic partners. Based in New York City but investing globally, Harmony was founded in 2010 by Mark Lotke, who has invested $1 billion in over 100 technology companies over the past 25 years, including Anaplan, AppDynamics, Alation, Arctic Wolf, E*Trade, Iterable, Klaviyo, Maven Clinic, Natera, Postmates, Priceline, SS&C, Swiggy, UiPath, and Zerto. To learn more, please visit www.harmonyvp.com. About Juxtapose Juxtapose is a creation-oriented investment firm that is exclusively focused on building industry-transforming businesses from the ground up. Founded by Patrick Chun and Jed Cairo in 2015, Juxtapose Ventures has supported the creation and financing of technology companies, including healthcare and tech businesses such as Care/of, Tend, Modern Age, and Forme Financial. Juxtapose partners with the world's most experienced and talented entrepreneurial operators to found and scale category-defining technology companies that are set up to win in the industries in which they operate. Read more at juxtapose.com. About Obvious Ventures Obvious Ventures is a venture capital firm investing in startups and entrepreneurs reimagining trillion-dollar industries through a world-positive lens. Since launching in 2014, Obvious has backed over 90 companies using technology to create a smarter, healthier, more sustainable world. The fund has led investments in breakthrough companies such as Beyond Meat, Olly, Virta Health, and Recursion. Obvious was co-founded by Ev Williams, James Joaquin, and Vishal Vasishth. More information is available at obvious.com. Contact:

Nectar Life Sciences Frequently Asked Questions (FAQ)

  • When was Nectar Life Sciences founded?

    Nectar Life Sciences was founded in 2021.

  • Where is Nectar Life Sciences's headquarters?

    Nectar Life Sciences's headquarters is located at 30 Cooper Square, New York.

  • What is Nectar Life Sciences's latest funding round?

    Nectar Life Sciences's latest funding round is Series A.

  • How much did Nectar Life Sciences raise?

    Nectar Life Sciences raised a total of $24.5M.

  • Who are the investors of Nectar Life Sciences?

    Investors of Nectar Life Sciences include Juxtapose, Obvious Ventures and Harmony Partners.

  • Who are Nectar Life Sciences's competitors?

    Competitors of Nectar Life Sciences include Upstream Bio and 8 more.

Compare Nectar Life Sciences to Competitors

Ro Logo
Ro

Ro is a patient-driven telehealth company that puts patients in control of their health. The company builds technology to make healthcare accessible, affordable, and enjoyable. Ro powers three digital health clinics: Roman for men’s health, Rory for women’s health, and Zero for fighting smoking cessation. It also operates Ro Pharmacy, a simple and affordable online pharmacy where every generic medication is $5 per month. Ro’s nationwide network of physicians and pharmacies provides a personalized, end-to-end healthcare experience from online treatment to the delivery of medication and ongoing care. The company was founded in 2017 and is based in New York, New York.

Intrommune Therapeutics Logo
Intrommune Therapeutics

Intrommune Therapeutics is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a therapeutic approach for the treatment of peanut and other food allergies. Intrommune’s mission is to develop safe and effective options for food allergy sufferers so they and their loved ones can live their lives without fear.

A
Allero Therapeutics

Allero Therapeutics is a biopharmaceutical company that develops immunotherapies for immune-mediated disorders.

Upstream Bio Logo
Upstream Bio

Upstream Bio develops a clinical-stage monoclonal antibody that inhibits the TSLP receptor. Its program aims to be positioned upstream in the inflammatory cascade with the potential to impact multiple diseases, including asthma. Upstream Bio serves clients operating in the healthcare sector. It was founded in 2021 and is based in Waltham, Massachusetts.

H
HealthMe

HealthMe is the digital shopping assistant for users who want to avoid certain foods or additives due to allergies, intolerances, or health awareness.

IgGenix Logo
IgGenix

InGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade. It was founded in 2019 and is based in San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.